TUESDAY, Sept. 6 (HealthDayNews) -- Parents and children may breathe a sigh of relief with the introduction of a new single shot vaccine that protects kids against measles, mumps, rubella and chickenpox…-- Forbes 9/6/05What costs more, naturally contracting chickenpox, or injecting a child with the chickenpox vaccine? Remember, the same sons of bitches at Merck who lied about Vioxx, and are now paying millions of dollars in damages in court cases, manufacture Proquad, the new combination vaccine.
"The FDA should have required far larger studies," said Barbara Loe Fisher, the co-founder and president of the National Vaccine Information Center. "You are combining five live viruses into one vaccine, which has never been done before." Fisher noted that there are still unanswered questions about some of these vaccines and the likelihood of having long-term adverse effects on children. "Particularly in regard to continuing reports of regression after MMR vaccine; the hypothesis that exposing children to three live viruses at once is causing some genetically susceptible children to regress and have a persistent measles infection leading to autism and intestinal bowel disorders," she said. As far as Proquad is concerned, Fisher said it hasn't been truly tested, because it has only been tested against other vaccines and not against a placebo. "With a new vaccine like this, you should be comparing it against placebo to find out the true adverse reaction rate."[emphasis added]—Forbes 9/6/05
All vaccines only provide temporary immunity. Only recovery from natural chickenpox disease will provide lifelong immunity. When the chickenpox vaccine was licensed for public use in 1995, the Food and Drug Administration (FDA) estimated that it was 70 to 90 percent effective in preventing disease. A recent Centers for Disease Control (CDC) study (Dec. 2002) reported that "the effectiveness of the vaccine was 44 percent against disease of any severity and 86 percent against moderate or severe disease." Some are suggesting a second dose of chickenpox vaccine may be needed. Another study in 2002 confirmed that adults exposed to natural chickenpox disease were protected from developing shingles and that there is concern that mass vaccination against chickenpox may cause a future epidemic of shingles, affecting more than 50 percent of Americans aged 10 to 44 years.[emphasis added]—National Vaccine Information Center
The upcoming generation of schoolchildren will require more special needs classroom facilities than are available under current budgets. Parents need to really become vigilant about the major increase in vaccine dosages over the past several decades. Parents need to face the question, is unloading a live virus toxin into an infant’s bloodstream really the best way to nurture that immature immune system?
The following is from an email newsletter from the NVIC:
Contact: Gary S. Goldman, Ph.D.
for immediate release
CHICKEN POX VACCINE ASSOCIATED WITH SHINGLES EPIDEMIC
Pearblossom, CA - New research published in the International Journal of Toxicology (IJT) by Gary S. Goldman, Ph.D., reveals high rates of shingles(herpes zoster) in Americans since the government's 1995 recommendation that all children receive chicken pox vaccine. Goldman's research supports that shingles, which results in three times as many deaths and five times the number of hospitalizations as chicken pox, is suppressed naturally by occasional contact with chicken pox.
Dr. Goldman's findings have corroborated other independent researchers who estimate that if chickenpox were to be nearly eradicated by vaccination, the higher number of shingles cases could continue in the U.S. for up to 50 years; and that while death rates from chickenpox are already very low, any deaths prevented by vaccination will be offset by deaths from increasing shingles disease. Another recent peer-reviewed article authored by Dr. Goldman and
published in Vaccine presents a cost-benefit analysis of the universal chicken pox (varicella) vaccination program. Goldman points out that during a 50-year time span, there would be an estimated additional 14.6million (42%) shingles cases among adults aged less than 50 years, presenting society with a substantial additional medical cost burden of $4.1 billion. This translates into $80 million annually, utilizing an estimated mean healthcare provider cost of $280 per shingles case.
After a child has had varicella (chickenpox), the virus becomes dormant and can reactivate later in adulthood in a closely related disease called shingles--both caused by the same varicella-zoster virus (VZV). It has long been known that adults receive natural boosting from contact with children infected with chicken pox that helps prevent the reactivation of shingles.
Based on Dr. Goldman's earlier communications with the Centers for Disease Control and Prevention (CDC), Goldman maintains that epidemiologists from the CDC are hoping "any possible shingles epidemic associated with the chickenpox vaccine can be offset by treating adults with a shingles vaccine." This intervention would substitute for the boosting adults previously received naturally, especially during seasonal outbreaks of the formerly common childhood disease. "Using a shingles vaccine to control shingles epidemics in adults would likely fail because adult vaccination programs have rarely proved successful," said Goldman. "There appears to be no way to avoid a mass epidemic of shingles lasting as long as several generations among adults."
Goldman's analysis in IJT indicates that effectiveness of the chickenpox vaccine itself is also dependent on natural boosting, so that as chickenpox declines, so does the effectiveness of the vaccine. "The principal reason that vaccines in Japan maintained high levels of immunity 20 years following vaccination was that only 1 in 5 (or 20%) of Japanese children were vaccinated," he said. "So those vaccinated received immunologic boosting from contact with
children with natural chickenpox. But the universal varicella vaccination program in the U.S. will nearly eradicate this natural boosting mechanism and will leave our population vulnerable to shingles epidemics."
For decades it was thought shingles increased with age as older
individuals' immune systems declined. However, Goldman's new research shows this phenomenon seemed primarily due to the fact that older people received fewer natural boosts to immunity as their contacts with young children declined.
Gary S. Goldman, Ph.D. served for eight years as a Research Analyst with the Varicella Active Surveillance Project conducted by the Los Angeles County Department of Health Services (LACDHS). The project was funded by the CDC.
About Gary S. Goldman, Ph.D.: Currently serves as Founder and
Editor-in-Chief of the peer-reviewed medical journal Medical Veritas (http://www.medicalveritas.com/). Has recently authored five manuscripts concerning varicella, herpes zoster, and capture-recapture published in the European journal called Vaccine.
Research published in the International Journal of Toxicology,
24(4):205-213, Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster. Also, Vaccine, 23(25):3349-3355, Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes zoster epidemiology.